CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Bio Path Holdings Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Bio Path Holdings Inc
4710 Bellaire Blvd Ste 210
Phone: (832) 742-1357p:832 742-1357 BELLAIRE, TX  77401-4505  United States Ticker: BPTH BPTH

Business Summary
Bio-Path Holdings, Inc. is a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company. It utilizes a technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body's enzymes when circulating in vivo, incorporated inside of a lipid bilayer having neutral charge. Its lead drug candidate, prexigebersen, targets growth factor receptor-bound protein 2 (Grb2). Its second drug candidate, Liposomal Bcl-2 (BP1002), targets the protein Bcl-2, which is responsible for driving cell survival in up to 60% of all cancers. Its third drug candidate, BP1003, targets the STAT3 protein. Its modified product named BP1001-A, is its fourth drug candidate for treatment of solid tumors.
(Source: 10-K)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/202312/31/2023YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board, President, Chief Executive Officer, Co-Founder, Chief Financial Officer, Tre Peter H.Nielsen 74 1/1/2008 1/1/2008
Director of Investor Relations, Secretary, Director Douglas P.Morris 67 12/31/2018 1/1/2007
Independent Director Paul D.Aubert 53 2/1/2018 2/1/2018
Independent Director Heath W.Cleaver 49 1/1/2014 1/1/2014
Independent Director AlineSherwood 3/31/2022 3/31/2022

Business Names
Business Name
Bio-Path, Inc.
BPTH

General Information
Number of Employees: 10 (As of 12/31/2023)
Outstanding Shares: 678,795 (As of 3/6/2024)
Shareholders: 187
Stock Exchange: NASD
Federal Tax Id: 870652870
Fax Number: (916) 443-1908


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, March 28, 2024